Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways.

PubWeight™: 0.90‹?›

🔗 View Article (PMID 26133775)

Published in Clin Cancer Res on July 01, 2015

Authors

Meredith A Morgan1, Theodore S Lawrence2

Author Affiliations

1: Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, Michigan. mmccrack@med.umich.edu.
2: Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, Michigan.

Associated clinical trials:

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer | NCT01847274

Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. | NCT01924533

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | NCT01386385

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer | NCT02163694

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma | NCT02044120

Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | NCT01514201

An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy | NCT02157792

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT02152982

Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours (Patriot) | NCT02223923

Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents | NCT02264678

Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas | NCT02037230

A Study of MK1775 in Combination With Topotecan/Cisplatin in Patients With Cervical Cancer (1775-008) | NCT01076400

A Phase 1 Dose-escalation Study of a Cell Cycle Inhibitor With and Without Gemcitabine in Patients With Solid Tumors or Lymphoma (Study P05248) | NCT00779584

Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC (olaparib) | NCT01562210

Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus (ROCOCO) | NCT01460888

A Study of ZSTK474 in Japanese Patients With Advanced Solid Malignancies | NCT01682473

Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia | NCT01870596

A Study for Patients With Pancreatic Cancer | NCT00839332

Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer | NCT01264432

WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas | NCT01922076

A Study in Non Small Cell Lung Cancer | NCT01139775

A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer | NCT01589419

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer | NCT02124148

NCT01343625

AZD1775 Plus Chemotherapy in Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02272790

Articles citing this

Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization. Int J Mol Sci (2016) 0.91

Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to HSP90 inhibition. Oncotarget (2015) 0.82

Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair. Neoplasia (2015) 0.80

Twist1 promotes radioresistance in nasopharyngeal carcinoma. Oncotarget (2016) 0.80

Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve. Br J Cancer (2016) 0.79

MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Oncotarget (2016) 0.79

Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry. Cell Cycle (2016) 0.75

Radiosensitizing effect of diosmetin on radioresistant lung cancer cells via Akt signaling pathway. PLoS One (2017) 0.75

A signature motif in LIM proteins mediates binding to checkpoint proteins and increases tumour radiosensitivity. Nat Commun (2017) 0.75

Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochim Biophys Acta (2017) 0.75

Differential expression profile analysis of DNA damage repair genes in CD133(+)/CD133(-) colorectal cancer cells. Oncol Lett (2017) 0.75

Chronic radiation exposure of neuroblastoma cells reduces nMYC copy number. Oncol Lett (2017) 0.75

Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget (2017) 0.75

Articles cited by this

Cell-cycle checkpoints and cancer. Nature (2004) 13.19

Targeting hypoxia in cancer therapy. Nat Rev Cancer (2011) 7.10

Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer (2008) 3.56

The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways. Nat Genet (2002) 2.97

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov (2012) 2.89

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol (2011) 2.85

Factors determining DNA double-strand break repair pathway choice in G2 phase. EMBO J (2011) 2.46

Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol (2011) 2.42

Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res (2010) 2.34

The influence of heterochromatin on DNA double strand break repair: Getting the strong, silent type to relax. DNA Repair (Amst) (2010) 2.24

Is there a link between DNA polymerase beta and cancer? Cell Cycle (2004) 2.10

ATR: a master conductor of cellular responses to DNA replication stress. Trends Biochem Sci (2010) 1.96

Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res (2010) 1.82

An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell (2012) 1.81

MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res (2011) 1.59

In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res (2010) 1.48

DNA repair. PAXX, a paralog of XRCC4 and XLF, interacts with Ku to promote DNA double-strand break repair. Science (2015) 1.38

The Mre11 complex mediates the S-phase checkpoint through an interaction with replication protein A. Mol Cell Biol (2007) 1.38

Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. Mol Cancer Res (2009) 1.37

RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. Nucleic Acids Res (2012) 1.36

Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther (2010) 1.34

Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis (2012) 1.32

Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. Oncogene (2012) 1.31

DNA DSB repair pathway choice: an orchestrated handover mechanism. Br J Radiol (2014) 1.31

Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response. Cancer Cell (2014) 1.30

DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front Oncol (2013) 1.30

The role of homologous recombination in radiation-induced double-strand break repair. Radiother Oncol (2011) 1.21

Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Mol Cancer Ther (2009) 1.20

Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys (2012) 1.19

ATM signalling and cancer. Oncogene (2013) 1.18

Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther (2011) 1.16

Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. PLoS One (2012) 1.16

ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin Cancer Res (2013) 1.15

Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin Radiat Oncol (2010) 1.14

Homologous recombination repairs secondary replication induced DNA double-strand breaks after ionizing radiation. Nucleic Acids Res (2012) 1.11

DNA single-strand break repair. Exp Cell Res (2014) 1.06

Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. Cell Cycle (2011) 1.05

Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Sci Transl Med (2013) 1.05

ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency. Cancer Res (2014) 1.03

Functional, genetic, and epigenetic aspects of base and nucleotide excision repair in colorectal carcinomas. Clin Cancer Res (2012) 0.97

Improving the efficacy of chemoradiation with targeted agents. Cancer Discov (2014) 0.97

Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. Clin Cancer Res (2014) 0.96

RPA inhibition increases replication stress and suppresses tumor growth. Cancer Res (2014) 0.95

Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment. Clin Cancer Res (2014) 0.95

Discovery of a potent inhibitor of replication protein a protein-protein interactions using a fragment-linking approach. J Med Chem (2013) 0.93

DNA-damage foci to detect and characterize DNA repair alterations in children treated for pediatric malignancies. PLoS One (2014) 0.90

Myc induced replicative stress response: How to cope with it and exploit it. Biochim Biophys Acta (2014) 0.89

A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts. PLoS One (2014) 0.89

Novel irreversible small molecule inhibitors of replication protein A display single-agent activity and synergize with cisplatin. Mol Cancer Ther (2011) 0.88

A stronger DNA damage-induced G2 checkpoint due to over-activated CHK1 in the absence of PARP-1. Cell Cycle (2006) 0.85

Targeted radiosensitization of cells expressing truncated DNA polymerase {beta}. Cancer Res (2010) 0.83

Membrane receptor signaling and control of DNA repair after exposure to ionizing radiation. Nuklearmedizin (2010) 0.83

Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget (2014) 0.83

From breaking bad to worse: exploiting homologous DNA repair deficiency in cancer. Cancer Discov (2014) 0.77

Articles by these authors

Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. Clin Cancer Res (2014) 0.96